We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

([content-module:CompanyOverview, NASDAQ:GILD) Gilead Sciences Inc. (NASDAQ:GILD) stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being ...

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster ...

The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech stock. Gilead reported fourth-quarter revenue of $7.6 billion, up 6% year over year.

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...